JP2023531090A5 - - Google Patents
Info
- Publication number
- JP2023531090A5 JP2023531090A5 JP2022580273A JP2022580273A JP2023531090A5 JP 2023531090 A5 JP2023531090 A5 JP 2023531090A5 JP 2022580273 A JP2022580273 A JP 2022580273A JP 2022580273 A JP2022580273 A JP 2022580273A JP 2023531090 A5 JP2023531090 A5 JP 2023531090A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010619111.6 | 2020-06-30 | ||
| CN202010620778 | 2020-06-30 | ||
| CN202010619083.8 | 2020-06-30 | ||
| CN202010619083 | 2020-06-30 | ||
| CN202010620778.8 | 2020-06-30 | ||
| CN202010619111 | 2020-06-30 | ||
| PCT/CN2021/103687 WO2022002153A1 (zh) | 2020-06-30 | 2021-06-30 | 用于治疗肿瘤的药物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023531090A JP2023531090A (ja) | 2023-07-20 |
| JPWO2022002153A5 JPWO2022002153A5 (https=) | 2024-07-09 |
| JP2023531090A5 true JP2023531090A5 (https=) | 2024-07-09 |
| JP7799638B2 JP7799638B2 (ja) | 2026-01-21 |
Family
ID=79317451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580273A Active JP7799638B2 (ja) | 2020-06-30 | 2021-06-30 | 腫瘍を治療するための薬物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230310596A1 (https=) |
| EP (1) | EP4174087A4 (https=) |
| JP (1) | JP7799638B2 (https=) |
| CN (1) | CN115698076A (https=) |
| AU (1) | AU2021301947A1 (https=) |
| CA (1) | CA3188017A1 (https=) |
| WO (1) | WO2022002153A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116209443A (zh) * | 2021-08-05 | 2023-06-02 | 正大天晴药业集团股份有限公司 | 治疗小细胞肺癌的药物组合 |
| CN119278053A (zh) * | 2022-06-02 | 2025-01-07 | 正大天晴药业集团股份有限公司 | 用于治疗子宫恶性肿瘤的药物组合 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10435470B2 (en) * | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| US9751859B2 (en) * | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| US11001631B2 (en) * | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| CN107460221B (zh) * | 2016-06-02 | 2021-01-15 | 正大天晴药业集团股份有限公司 | 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法 |
| CN110573172A (zh) * | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3577133A1 (en) * | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| US20210147547A1 (en) * | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| CN113861295B (zh) * | 2018-07-20 | 2024-05-24 | 厦门大学 | 抗pd-1抗体及其用途 |
| AU2020212767B2 (en) * | 2019-01-25 | 2025-01-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition for treating tumor |
| CN112168961A (zh) * | 2019-07-03 | 2021-01-05 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗结直肠癌的联用药物组合物 |
-
2021
- 2021-06-30 WO PCT/CN2021/103687 patent/WO2022002153A1/zh not_active Ceased
- 2021-06-30 CA CA3188017A patent/CA3188017A1/en active Pending
- 2021-06-30 EP EP21833511.5A patent/EP4174087A4/en active Pending
- 2021-06-30 US US18/003,718 patent/US20230310596A1/en active Pending
- 2021-06-30 AU AU2021301947A patent/AU2021301947A1/en active Pending
- 2021-06-30 JP JP2022580273A patent/JP7799638B2/ja active Active
- 2021-06-30 CN CN202180041400.5A patent/CN115698076A/zh active Pending